Hims & Hers Health’s (HIMS) Sell Rating Reaffirmed at Citigroup

Hims & Hers Health (NYSE:HIMS)‘s stock had its “sell” rating restated by stock analysts at Citigroup in a report issued on Thursday,Benzinga reports. They presently have a $27.00 target price on the stock. Citigroup’s price objective points to a potential downside of 28.04% from the stock’s previous close.

Several other research analysts also recently commented on the company. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Bank of America raised their target price on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research report on Thursday, February 20th. TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Needham & Company LLC boosted their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $37.23.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded down $3.37 during trading on Thursday, hitting $37.52. 11,616,706 shares of the stock were exchanged, compared to its average volume of 12,982,556. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a market capitalization of $8.34 billion, a price-to-earnings ratio of 85.28 and a beta of 1.37. The company’s fifty day simple moving average is $37.34 and its 200-day simple moving average is $27.27.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. On average, research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 85,561 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $31.01, for a total value of $2,653,246.61. Following the transaction, the chief operating officer now owns 630,986 shares in the company, valued at approximately $19,566,875.86. This trade represents a 11.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $4,659,976.07. This represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,062,011 shares of company stock valued at $36,892,724 in the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after buying an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Renaissance Technologies LLC grew its position in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, State Street Corp boosted its holdings in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after buying an additional 206,078 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.